![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: TFPI |
Gene summary for TFPI |
![]() |
Gene information | Species | Human | Gene symbol | TFPI | Gene ID | 7035 |
Gene name | tissue factor pathway inhibitor | |
Gene Alias | EPI | |
Cytomap | 2q32.1 | |
Gene Type | protein-coding | GO ID | GO:0002237 | UniProtAcc | P10646 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
7035 | TFPI | AEH-subject2 | Human | Endometrium | AEH | 2.29e-05 | -9.00e-02 | -0.2525 |
7035 | TFPI | AEH-subject3 | Human | Endometrium | AEH | 1.70e-04 | -1.45e-01 | -0.2576 |
7035 | TFPI | AEH-subject4 | Human | Endometrium | AEH | 3.62e-02 | -3.74e-02 | -0.2657 |
7035 | TFPI | EEC-subject1 | Human | Endometrium | EEC | 4.70e-07 | -1.47e-01 | -0.2682 |
7035 | TFPI | EEC-subject2 | Human | Endometrium | EEC | 3.89e-10 | -1.56e-01 | -0.2607 |
7035 | TFPI | EEC-subject3 | Human | Endometrium | EEC | 5.38e-05 | -3.19e-02 | -0.2525 |
7035 | TFPI | EEC-subject5 | Human | Endometrium | EEC | 7.78e-06 | -1.41e-01 | -0.249 |
7035 | TFPI | GSM5276934 | Human | Endometrium | EEC | 1.00e-18 | 5.41e-01 | -0.0913 |
7035 | TFPI | GSM5276935 | Human | Endometrium | EEC | 4.30e-04 | -1.30e-01 | -0.123 |
7035 | TFPI | GSM5276937 | Human | Endometrium | EEC | 2.01e-19 | 5.60e-01 | -0.0897 |
7035 | TFPI | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 6.41e-05 | -1.42e-01 | -0.1869 |
7035 | TFPI | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 9.87e-05 | -1.56e-01 | -0.1875 |
7035 | TFPI | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 6.46e-06 | -1.56e-01 | -0.1883 |
7035 | TFPI | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 8.71e-07 | -1.56e-01 | -0.1934 |
7035 | TFPI | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 1.89e-07 | -1.56e-01 | -0.1917 |
7035 | TFPI | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 2.91e-09 | -1.12e-01 | -0.1916 |
7035 | TFPI | LZE2T | Human | Esophagus | ESCC | 4.49e-03 | 3.59e-01 | 0.082 |
7035 | TFPI | LZE8T | Human | Esophagus | ESCC | 3.38e-17 | 9.25e-01 | 0.067 |
7035 | TFPI | P4T-E | Human | Esophagus | ESCC | 3.84e-21 | 9.49e-01 | 0.1323 |
7035 | TFPI | P8T-E | Human | Esophagus | ESCC | 1.72e-16 | 5.06e-01 | 0.0889 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00075969 | Oral cavity | OSCC | blood coagulation | 102/7305 | 217/18723 | 9.69e-03 | 3.43e-02 | 102 |
GO:00075999 | Oral cavity | OSCC | hemostasis | 103/7305 | 222/18723 | 1.45e-02 | 4.73e-02 | 103 |
GO:00508179 | Oral cavity | OSCC | coagulation | 103/7305 | 222/18723 | 1.45e-02 | 4.73e-02 | 103 |
GO:004206026 | Oral cavity | EOLP | wound healing | 99/2218 | 422/18723 | 1.18e-11 | 1.85e-09 | 99 |
GO:005254725 | Oral cavity | EOLP | regulation of peptidase activity | 105/2218 | 461/18723 | 1.86e-11 | 2.79e-09 | 105 |
GO:005254825 | Oral cavity | EOLP | regulation of endopeptidase activity | 98/2218 | 432/18723 | 1.12e-10 | 1.29e-08 | 98 |
GO:004854526 | Oral cavity | EOLP | response to steroid hormone | 75/2218 | 339/18723 | 5.18e-08 | 1.92e-06 | 75 |
GO:007138325 | Oral cavity | EOLP | cellular response to steroid hormone stimulus | 49/2218 | 204/18723 | 8.63e-07 | 2.15e-05 | 49 |
GO:004586125 | Oral cavity | EOLP | negative regulation of proteolysis | 72/2218 | 351/18723 | 1.96e-06 | 4.49e-05 | 72 |
GO:003235522 | Oral cavity | EOLP | response to estradiol | 36/2218 | 141/18723 | 5.44e-06 | 1.08e-04 | 36 |
GO:001095124 | Oral cavity | EOLP | negative regulation of endopeptidase activity | 52/2218 | 252/18723 | 4.21e-05 | 5.74e-04 | 52 |
GO:190303419 | Oral cavity | EOLP | regulation of response to wounding | 38/2218 | 167/18723 | 5.06e-05 | 6.58e-04 | 38 |
GO:006104117 | Oral cavity | EOLP | regulation of wound healing | 32/2218 | 134/18723 | 7.29e-05 | 8.89e-04 | 32 |
GO:003249623 | Oral cavity | EOLP | response to lipopolysaccharide | 65/2218 | 343/18723 | 8.02e-05 | 9.65e-04 | 65 |
GO:005134625 | Oral cavity | EOLP | negative regulation of hydrolase activity | 70/2218 | 379/18723 | 9.98e-05 | 1.14e-03 | 70 |
GO:001046624 | Oral cavity | EOLP | negative regulation of peptidase activity | 52/2218 | 262/18723 | 1.21e-04 | 1.34e-03 | 52 |
GO:000223724 | Oral cavity | EOLP | response to molecule of bacterial origin | 67/2218 | 363/18723 | 1.42e-04 | 1.53e-03 | 67 |
GO:00321023 | Oral cavity | EOLP | negative regulation of response to external stimulus | 75/2218 | 420/18723 | 1.74e-04 | 1.80e-03 | 75 |
GO:005081715 | Oral cavity | EOLP | coagulation | 43/2218 | 222/18723 | 7.59e-04 | 6.09e-03 | 43 |
GO:000759615 | Oral cavity | EOLP | blood coagulation | 42/2218 | 217/18723 | 8.81e-04 | 6.76e-03 | 42 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04610 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa046101 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa046102 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa046103 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa046104 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
hsa046105 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TFPI | SNV | Missense_Mutation | novel | c.295N>C | p.Glu99Gln | p.E99Q | P10646 | protein_coding | deleterious(0.03) | possibly_damaging(0.851) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TFPI | SNV | Missense_Mutation | rs746176720 | c.637N>A | p.Gly213Ser | p.G213S | P10646 | protein_coding | tolerated(0.39) | benign(0.44) | TCGA-D8-A1Y1-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | PD |
TFPI | SNV | Missense_Mutation | rs781414695 | c.889N>A | p.Glu297Lys | p.E297K | P10646 | protein_coding | tolerated(0.16) | possibly_damaging(0.709) | TCGA-UC-A7PF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
TFPI | SNV | Missense_Mutation | c.238G>A | p.Glu80Lys | p.E80K | P10646 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
TFPI | SNV | Missense_Mutation | c.821G>T | p.Arg274Ile | p.R274I | P10646 | protein_coding | deleterious(0) | possibly_damaging(0.641) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
TFPI | SNV | Missense_Mutation | c.706N>G | p.Asn236Asp | p.N236D | P10646 | protein_coding | tolerated(0.12) | probably_damaging(0.925) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
TFPI | SNV | Missense_Mutation | c.730N>A | p.Pro244Thr | p.P244T | P10646 | protein_coding | deleterious(0.04) | possibly_damaging(0.651) | TCGA-CK-5913-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
TFPI | SNV | Missense_Mutation | rs568113767 | c.173N>T | p.Ala58Val | p.A58V | P10646 | protein_coding | tolerated(0.11) | benign(0.101) | TCGA-DM-A1HB-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
TFPI | insertion | Frame_Shift_Ins | novel | c.755_756insG | p.Asn253LysfsTer2 | p.N253Kfs*2 | P10646 | protein_coding | TCGA-DM-A1D4-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | ||
TFPI | SNV | Missense_Mutation | novel | c.419N>T | p.Arg140Met | p.R140M | P10646 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7035 | TFPI | CELL SURFACE, DRUGGABLE GENOME, PROTEASE INHIBITOR | PI-88 | MUPARFOSTAT | 11292191 | |
7035 | TFPI | CELL SURFACE, DRUGGABLE GENOME, PROTEASE INHIBITOR | CHONDROITIN SULFATE | 10959709 | ||
7035 | TFPI | CELL SURFACE, DRUGGABLE GENOME, PROTEASE INHIBITOR | AZITHROMYCIN | AZITHROMYCIN | 16113783 | |
7035 | TFPI | CELL SURFACE, DRUGGABLE GENOME, PROTEASE INHIBITOR | HEPARIN | HEPARIN | 11150580 | |
7035 | TFPI | CELL SURFACE, DRUGGABLE GENOME, PROTEASE INHIBITOR | NN-7415 | |||
7035 | TFPI | CELL SURFACE, DRUGGABLE GENOME, PROTEASE INHIBITOR | LOVASTATIN | LOVASTATIN | 7600119 | |
7035 | TFPI | CELL SURFACE, DRUGGABLE GENOME, PROTEASE INHIBITOR | CREMOPHOR | 9352228 | ||
7035 | TFPI | CELL SURFACE, DRUGGABLE GENOME, PROTEASE INHIBITOR | ATORVASTATIN | ATORVASTATIN | 15792677 | |
7035 | TFPI | CELL SURFACE, DRUGGABLE GENOME, PROTEASE INHIBITOR | FULVESTRANT | FULVESTRANT | 17029634 | |
7035 | TFPI | CELL SURFACE, DRUGGABLE GENOME, PROTEASE INHIBITOR | CHONDROITIN | 7974391 |
Page: 1 2 |